The role of uric acid in pediatric hypertension.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanistic models, cross-sectional data, and preliminary trials without presenting primary quantitative data.
PubMed 17198939 · doi:10.1053/j.jrn.2006.10.013
What was done
The authors summarized findings from animal models, tissue culture experiments, cross-sectional studies, and clinical trials examining the mechanistic and clinical role of uric acid in pediatric essential hypertension.
What was found
No quantitative data, sample sizes, or numerical effect sizes are reported in the abstract. The authors report that mechanistic studies show uric acid induces a two-phase process (initial vasoconstriction followed by renal afferent arteriolosclerosis and altered pressure natriuresis), that elevated uric acid is closely associated with new-onset pediatric essential hypertension, and that preliminary data suggest lowering uric acid can reduce blood pressure in some patients.
Why it matters
It highlights uric acid as a potential direct mediator and modifiable target in the early pathogenesis of pediatric hypertension rather than merely an incidental marker.
Limits
The abstract provides no quantitative metrics, exact sample sizes, patient characteristics, or details on the preliminary clinical trial designs. Human findings rely on preliminary data, and the generalizability of the mechanistic animal models to children remains unproven.
Cited by
- supports Approximately 90% of adolescents with newly diagnosed primary essential hypertension have elevated serum uric acid, compared to under 5% of normotensive controls.